Consulting

Recovering from an Unsatisfactory/Disastrous Pre-IND Meeting

Recovering from an Unsatisfactory/Disastrous Pre-IND Meeting

This presentation is part of a series of webinars on 505(b)(2) NDA drug development that highlights the diversity, simplicity, and complexity of the 505(b)(2) application process. This session discusses pre-IND meetings for 505(b)(2) product development, with a focus on inadequate pre-IND examples and recovery plans for unsatisfactory meetings.

Speaker: Angela Drew, PhD, Vice President, Regulatory Strategy

View the other webinars in the series here:

 

Ready to get started? So are we.

Drop us a line to learn more about how we can help.